Key result
The cost utility method of ranking treatments used by development and evaluation committees may lead to poor decision making due to strong assumptions and selective use of evidence.
Answers are grounded in this paper and cite their sources.
The appraisal process for new drugs by NICE, mirroring regional development and evaluation committees, may be inadequate due to inappropriate cost utility methods.
The consultation document A First Class Service: Quality in the New NHS 1 heralded the introduction of the National Institute for Clinical Excellence (NICE). A key task of the institute is to provide rapid appraisal of new drugs in the period before licensing. New products may be accepted or refused NHS reimbursement, or they may be allocated “continuing research status.” The review process described in A First Class Service and developed in a subsequent discussion paper2 mirrors that used for regionally funded development and evaluation committee (DEC) reports. Development and evaluation committee reports are produced by an independent arbitration committee comprising senior clinicians and others, who review the quality of available evidence, give explicit consideration to cost utility estimates, and make recommendations about interventions. Reports are published by NHS Research and Development (www.epi.bris.ac.uk/rd). Are the methods used by the development and evaluation committee up to the task? #### Summary points The National Institute for Clinical Excellence will appraise 30-50 drugs and technologies each year to inform decisions on whether these should be accepted or refused NHS reimbursement The appraisal process will mirror that of regional development and evaluation committees, but this may lead to poor decision making since the methods used are inappropriate The cost utility method of ranking treatments is based on strong assumptions and selective use of available evidence New drugs should be appraised in terms of physical outcomes that mean something to doctors and patients Because of limited resources and medical cost inflation, new drugs can place a considerable strain on prescribing budgets.3 New and expensive drugs can benefit patients, but only if worthwhile advances can be differentiated from costly ways of achieving equivocal results. However, new drugs present particular difficulties; they have usually been evaluated in relatively few clinical trials in which measures of effectiveness are narrow—and …
No takes yet. Share an insight, caveat, or question.
Freemantle et al. (1999) reported an editorial. Cost utility method for drug appraisal was evaluated. The cost utility method of ranking treatments used by development and evaluation committees may lead to poor decision making due to strong assumptions and selective use of evidence.
Synapse has enriched 10 related papers. Consider them for comparative context: